CV For Dr. Unger
CURRICULUM VITAE
Jeffrey R. Unger, MD, ABFP, FACE
(Updated August 18, 2015)
Business Locations:
Concierge Private Medicine Practice
Unger Primary Care
9220 Haven Ave; Suite 230
Rancho Cucamonga, Ca. 91730
Phone: 909-484-2105
Website: ungerprimarycare.com
Society Memberships:
American Academy of Family Practice
California Academy of Family Physicians
American Headache Society
American Council of Headache Education
National Headache Foundation
American Diabetes Association
American Association of Clinical Endocrinologists
Primary Care Headache Network
Primary Care Metabolic Group
Primary Care Education Consortium
Headache Cooperative of the Pacific
American Academy of Private Physicians
Fellowships:
American Board of Family Practice (11/2012)
American Association of Clinical Endocrinologists (5/17/14)
Papers and Publications (Journal Articles):
1) Unger, Jeffrey R. & Jacobsen, David: “Infection Complication Biopsy in Lactating Breast”- American Family Practice, Feb. 1981.
2) Unger, Jeffrey: “Intensive Care Wedding”-Resident and Staff Physician, Feb. 1981.
3) Unger, Jeffrey R. and Amin, Navin M.: “Syndrome of Inappropriate Antidiuretic hormone Secretion”- Family Practice Recertification, March 1981.
4) Unger, Jeffrey R. & Amin, Navin, M.: “Tip on Treatment of Nasal Spray Abuse”-Consultant, May 1983.
5) Unger, Jeffrey R.: “Tip on Emergency Room Splinting of Nasal Fractures”-Emergency Medicine, March 1983.
6) Amin, Navin M. & Unger, Jeffrey R.: “Photoclinic: Osler-Weber-Rendu Syndrome”-Consultant, August 1983.
7) Unger, Jeffrey R. & Amin, Navin M.: “Toxoplasmosis”-Family Practice Recertification, Nov. 1983
8) Amin, Navin M. & Unger, Jeffrey R.: “Photoclinic: Rendu-Osler-Weber Disease”-Medical Times, Feb. 1983.
9) Unger, Jeffrey R.: “Headache Diagnosis and Management, Part I”-Hospital Physician, Feb 1994.
10) Unger, Jeffrey R.: “Headache Diagnosis and Management, Part II”-Hospital Physician, March 1994.
11) Unger, Jeffrey R.: “Low Central Spinal Fluid Pressure Headaches” Letter to the Editor, Hospital Physician, July 1994.
12) Unger, Jeffrey R.: “Intensive Insulin Therapy”-Hospital Physician, Nov. 1994
13) Unger, Jeffrey R. & Fredrickson Linda P. A primer on Intensive Diabetes Management and Insulin Pump Therapy. Primary Care Reports. 3 (2). 9-18. 1997.
14) Unger, Jeffrey R.: “Issues to consider in selecting candidates for zolmitriptan therapy.” Postgraduate Medicine, Jan. , 1998.
15) Unger, Jeff: “A Primary Care Approach to Continuous Subcutaneous Insulin Infusion.” Clinical Diabetes. July 1999. Vol. 17, No. 3 Pages 113-120.
16) Unger, Jeff: “Intensive Insulin Management of Type 1 Diabetes in the Female Patient.” The Female Patient. Vol. 24, No. 12. Pages 35-42. Dec. 1999.
17) Unger JR, Chronic Daily Headache Part 1: Classification and Evaluation. The Female Patient. Vol. 25. P73-78. August 2000.
18) Unger JR, Chronic Daily Headache Part 2: Management Options. The Female Patient. Vol.25. P .73-77. September. 2000
19) Skyler JS, Unger JR, Heile M: Audio-Digest: Controlling Sugar Surges. Family Practice. Volume 48, Issue 22. June 14, 2000.
20) Unger JR, Chronic Daily Headache, Part 1: Classification and Evaluation. The Female Patient- OB/GYN edition. Vol. 25. P 14-27. Aug. 2000.
21) Unger JR, Chronic Daily Headache, Part 2: Management Options. The Female Patient- OB/GYN edition. Vol. 25. Sept. 2000.
22) Unger Jeff, What is Chronic Daily Headache? NHF Headlines. Sept/Oct. 2000. Volume 116. P1-3.
23) Bedell AW, Cady RK, Diamond ML, Farmer KU, Friesen CP, Johnson JM, Kaniecki RG, Lake AE, Loder E, Maizels M, Mannix LK, Martin V, Ruoff GE, Schreiber CP, Sheftel FP, Smith TR, Taylor FR, Thompson TL, Unger JR. Patient-Centered Strategies for Effective Management of Migraine. Primary Care Network. 2000.
24) Unger, Jeff. Chronic Daily Headache (Part 2). NHF Headlines. Nov/Dec. 2000. Volume 117. P6-7.
25) Unger J. Preconception Management of Women with Type 1 Diabetes. The Female Patient. Vol 26. 40-46. May 2001.
26) Unger J. Diabetes Management in the New Millenium (Editorial-Primary Care Edition). The Female Patient. Vol. 26. P 10-11. May 2001.
27) Unger J. Diabetes Management in the New Millenium (Editorial-OB/GYN Edition). The Female Patient. Vol. 26. P 10-12. May 2001.
28) Unger J. Preconception Management of Women with Type 1 Diabetes. The Female Patient (OB/GYN edition). Vol. 26. P 45-51. 2001.
29) Shuldiner AR, Goldstein BJ, O’Keefe JH, Safford MM, Unger J. Controlling Type 2 Diabetes: Debating Clinical Strategies and Cardiovascular Connections? Medical Crossfire. Vol 3, N.6 P 1-10. 2001.
30) Unger J. Intensive Management of Type 1 Diabetes. Home Health Care Consultant. 8 (6):7-17. 2001.
31) Unger J. Intensive Management of Type 1 Diabetes. Emergency Medicine 33 (9): 30-42. 2001.
32) Unger J. Intensive Management of Type 2 Diabetes. Emergency Medicine33 (10): P 28-43. 2001
33) Unger Jeff. Case Study: A 62 year-old man with “Brittle” Type 1 Diabetes. Clinical Diabetes.2002. 20 (1): 37-39.
34) Cady RK, Weidman E, Unger J, Farmer KU. Pediatric Migraine. Primary Care Network 3/17/02. http://www.primarycarenet.org/cme/CME11.CFM.
35) Unger, J. Headache Disorders in Women. How to identify and treat. Women’s Health Primary Care. 2002:5 (4): 248-260.
36) Unger J, Marcus A. Insulin Pump Therapy. What You Need To Know.Emergency Medicine. 34 (9). P24-33. 2002.
37) Unger Jeff. Type 2 Diabetes Patients Need Intensive Management. Primary Care Network, Primary Issues. 2002:4(4) 1-3.
38) Unger Jeff. Headache Disorders in Women. How to Identify and treat.Women’s Health in Primary Care.GYN edition.2002: 2(7). P 395-404.
39) Unger, Jeff. Improving Compliance While Intensively Managing Diabetes. Physician’s Weekly. 2002: 4(42). 1.
40) Unger, Jeff. Screening, Treatments Reduce Toll from Osteoporosis. Primary Care Network, Primary Issues. 2002: 6 (6). P1-3.
41) Unger, Jeff. Diabetic Hypertension. Medical Crossfire. 2002: 4 (12). P.18.
42) Weidman E, Unger J, Blair S, Friesen C, Hart C, Cady R. An open-label study to assess changes in efficacy and satisfaction with migraine care when patients have acess to multiple sumatriptan succinate formulations. Clinical Therapeutics.2003: 25 (1), 235-246.
43) Unger Jeff, Cady Roger K, Farmer-Cady Kathleen. Migraine Headaches, Part 1: Presentation and Diagnosis. The Female Patient. May 2003: Vol.28. 14-21.
44) Unger Jeff, Cady Roger K, Farmer-Cady Kathleen, Migraine Headaches, Part 2: Treatment Options. The Female Patient. June, 2003: Vol 28. 1-8.
45) Unger Jeff, Cady Roger K, Farmer-Cady Kathleen. Migraine Headaches, Part 1: Presentation and Diagnosis. The Female Patient OB/GYN Edition. May 2003. Vol 28. 32-39.
46) Unger Jeff, Cady, Roger K, Farmer-Cady Kathleen. Migraine Headaches. Part 2. The Female Patient. June 2003. Vol. 28. 22-29.
47) Unger Jeff, Cady, Roger K, Farmer-Cady Kathleen. Migraine Headaches. Part 2. The Female Patient. Ob/Gyn edition. June 2003. Vol. 28. 22-29
48) Unger Jeff, Cady Roger K, Farmer-Cady Kathleen. Migraine Headaches, Part 3: Hormonal Factors. The Female Patient. Primary Care Edition. July 2003. Vol 28, P31-34.
49) Unger Jeff, Cady Roger K, Farmer-Cady Kathleen. Migraine Headaches, Part 3: Hormonal Factors. The Female Patient.Ob/Gyn Edition. July 2003. Vol. 28, P 24-27
50) Unger Jeff, Cady Roger K, Farmer-Cady Kathleen. Understanding Migraine: Pathophysiology and Presentation. Emergency Medicine. Aug. 2003. 22-32 .
51) Unger Jeff. Targeting Glycemic Control in the Primary Care Setting. The Female Patient. Sept. 2003. Vol. 28. P 12-16.
52) Unger Jeff, Cady Roger K, Farmer-Cady Kathleen. Understanding Migraine: Treatment Options. Emergency Medicine. Sept. 2003. 50-55
53) Unger Jeff, Cady Roger K, Farmer-Cady Kathleen. Understanding Migraine: Strategies for Prevention. Emergency Medicine. Oct. 2003. 39-45.
54) Unger Jeff. Primary Care Docs Beware: We Can Prevent Heart Disease!” The Female Patient. Vol. 28 Oct. 2003. 10-11.
55) Unger Jeff. Targeting Glycemic Control. The Female Patient. Health Care Edition. Nov. 2003. Vol. 28. P. 22-29.
56) Unger Jeff. How To Assess and Treat Erectile Dysfunction. Emergency Medicine. Jan. 2004. Vol. 36. No. 1. P 28-37.
57) Unger Jeff. Diagnosing and Managing Insulin Resistance Syndrome. Emergency Medicine. Feb. 2004. Vol. 28. P. 36-43.
58) Unger Jeff, Marcus Alan O. Glucose control in the hospitalized patient. Emergency Medicine. Sept. 2004. 12-18.
59) Unger Jeff. Screening for type 2 diabetes in primary care. The Female Patient. Vol.29. Sept. 2004. 27-29.
60) Unger Jeff. The Challenge of Managing Chronic Pain in Primary Care: What Critical Historical Clues Are We Missing? Editorial. The Female Patient. Primary Care Edition. Vol. 29 Nov. 2004. P. 8-9.
61) Unger Jeff. The Challenge of Managing Chronic Pain in Primary Care: What Critical Historical Clues Are We Missing? Editorial. The Female Patient. OB/GYN Edition. Vol. 29 Nov. 2004. P. 8-9.
62) Brackenridge B, Brunton S, Kruger DF, Mora PF, Unger J, Wick AK, Salgo PL. Keys to Maximizing Outcomes in Type 2 Diabetes. Driving a Path to Success. Medical Crossfire. Vol. 5 Oct. 2004. P-18.
63) Unger, Jeff. Diabetic Neuropathy. Early Clues. Effective Management. Consultant. Oct. 2004. 1549-1556.
64) Unger J. Fine-Tuning Physiologic Insulin Replacement Therapy With Office Based Home Blood Glucose Monitoring Downloading Software Systems. The Female Patient. Vol 30 March 2005. P 29-36.
65) Unger Jeff. Diabetic Neuropathy: Early Clues, Effective Management. Applied Neurology. Sept. 2005. P 23-30.
66) Unger, Jeff.Diagnosis and Management of Diabetic Peripheral Neuropathic Pain. The Female Patient. Primary Care Edition. Vol. 30 (8). 27-33. 2005
67) Unger J. Glucose regulations and clinical shortcomings. Diabetes Consult Collection. A Supplement to Emergency Medicine. April 2006. 3-4.
68) Unger J. Novel insulin replacement. Diabetes Consult Collection. A Supplement to Emergency Medicine. April 2006. 10-14.
69) Unger J., Stanley P. Migraine Management FAQs. Supplement to Clinician Reviews. April 2006.
70) Unger, Jeff. Managing mental illness in patients with diabetes. Practical Diabetology. 25 (2); 44-53. 2006.
71) Unger J. Pediatric migraine: Diagnosis, classification, precursors and treatment. Applied Neurology; 2 (6). 26-31. 2006
72) Unger J. Pediatric migraine: Clinical Pearls in Diagnosis and Therapy. Headache & Pain Diagnostic Challenges. Current Therapy. 17 (3) 104-113. 2006.
73) Schmaderer J, Unger J. Dietary Guidelines for Americans. The Female Patient. 31 (9). 34-40. 2006.
74) Unger J. Why has tight glycemic control become the standard of care for Type 2 Diabetes? Diabetes Consult Collection. 3-5. Sept. 2006.
75) Unger J. Encouraging intensification of type 2 diabetes management using insulin therapy within the primary care setting-a call to action. Diabetes Consult Collection. 6-10. Sept. 2006.
76) Brunton S, Unger J. Options for initiating and intensifying insulin therapy in type 2 diabetes. Diabetes Consult Collection. 14-23. Sept. 2006.
77) Unger J. Pediatric Migraine: Clinical Pearls in Diagnosis and Therapy. Consultant for Pediatricians. 5 (9). 545-551. 2006
78) Unger J. Practical strategies for achieving targeted glycemic control in patients with type 2 diabetes. Supplement to The Journal of Family Practice. December 2006. 25-32. http://www.jfponline.com/uploadedFiles/Journal_Site_Files/Journal_of_Family_Practice/supplement_archive/JFPSupp_InsulinFP_1206.pdf.
79) Unger. J. Introduction to Migraine Consult Collection. A Supplement to The Female Patient. March 2007. P. 11.
80) Unger J., Krusz JC. Understanding migraine pathophysiology: A foundation for treatment. Migraine Consult Collection. A Supplement to The Female Patient. March 2007. P. 12-25.
81) Unger J. Pathogenesis, diagnosis, and treatment of painful diabetic peripheral neuropathy. Applied Neurology. Feb. 2007. Supplement 1. 6-15.
82) Unger J. Migraine prophylaxis. The Pain Practitioner. 17 (1). 32-36. 2007.
83) Freitag FG, Finlayson G, Rapoport AM, Elkind AH, Diamond ML, Unger JR, Fisher AC, Armstrong RB, Hulihan JF, Greenberg SJ. Effect of pain intensity and time to administration of responsiveness to almotriptan: Results from AXERT 12.5 mg versus intensity migraine study (AIMS). Headache. 47: 519-530. 2007.
84) Unger J, Nadeau DA. Defining the role of incretin mimetic therapy in the management of type 2 diabetes. Supplement to the Journal of Family Practice. 2007. S4-S10.
85) Unger J. Obstacles surrounding the diagnosis and management of diabetic neuropathy. The Pain Practitioner. 2007. 17 (3). 33-42.
86) Unger, J. Early clues lead to effective neuropathy management. Biomechanics. March 2006. 41-49.
87) Unger, Jeff. Current strategies for evaluating, monitoring and treating type 2 diabetes mellitus. Supplement to The American Journal of Medicine. 121 (6) S3-S8. 2008.
88) Unger, Jeff. Introduction to Supplement Volume 121 of the American Journal of Medicine. 2008. 121 (6) S1-S2. 2008.
89) Unger, Jeff. Diagnosing and managing latent autoimmune diabetes in adults. Practical Diabetology. 21(1): 32-37. March 2008
90) Unger Jeff. Reducing oxidative stress in patients with type 2 diabetes mellitus: A Primary Care call to action. Insulin. 2008;3:176-184.
91) Freeman JS, Unger J. Why and when to implement incretin therapy. Supplement to the Journal of Family Practice. Sept. 2008. 57 (9). S10-S16.
92) Brunton S, Tenzer-Iglesias P, Unger J. Initiating and intensifying therapy in type 2 diabetes: Managing the progressive nature of the disease. The Journal of Family Practice. 2008. 57 (10). S17-S26.
93) Unger, Jeff. Brittle Diabetes: Drilling down to the cause. Emergency Medicine. 2009. 41 (4). 35-40.
94) Unger J, Parkin C. Appropriate, timely and rational treatment of type 2 diabetes mellitus: Meeting the challenges of primary care. Insulin 2009;4:144-157.
95) Unger Jeff. Latent Autoimmune Diabetes In Adults (Editorial). American Family Physician. 81(7). March 2010. 843-847.
96) Unger Jeff. Choosing among the incretin agents and why it matters. Supplement to the Journal of Family Practice. 2010. 59 (5). 30-35.
97) Unger Jeff, Parkin Christopher G. Type 2 Diabetes: An expanded view of pathophysiology and therapy. Postgraduate Medicine. 122 (3). 2010. 145-157.
98) Unger J. Liraglutide: Can it make a difference in the treatment of type 2 diabetes? International Journal of Clinical Practice. 2010. (Suppl 167). 1-3.
99) Unger J. Incretins: Clinical perspectives, relevance, and applications for the primary care physician in the treatment of patients with type 2 diabetes. Mayo Clinic Proceedings. Dec 2010 85 (12) (Suppl): S38-S49.
100) Unger, J. Comparing the efficacy, safety and utility of intensive insulin algorithms for a primary care practice. Diabetes Therapy. 2011. 2 (1). 1-11.
101) Unger J. Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm. J Am Osteopath Assoc. 2011;111 (2 suppl 1):eS2-eS9.
102) Unger J, Parkin C. Recognition, prevention and proactive management of hypoglycemia in patients with type 1 diabetes. Postgraduate Medicine. 2011. 123 (4). 71-80
103) Unger J, Parkin C. Hypoglycemia in Insulin-Treated Diabetes: A Case for Increased Vigilance. Postgraduate Medicine. 2011. 123 (4). 81-91.
104) Unger J. Insulin initiation and intensification in patients with T2DM for the primary care physician. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2011:4 253–261.
105) Unger J, Parkin C. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists:Differentiating the new medications. Diabetes Therapy. 2011. 2(1):29-39.
106) Rodbard HW, Schnell O, Unger J, et al. Use of an automated decision support tool optimizes clinicians ability to interpret and appropriately respond to structured self-monitoring of blood glucose data. Diabetes Care. 2012. doi: 10.2337/dc11-1351. 35 (4). 693-698.
107) Unger J. Uncovering undetected hypoglycemic events. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2012. 5 (1). 57-74.
108) Unger J. Advances in Diabetes Therapies. Federal Practitioner. 2012. 29 (Suppl 1). 18S-24S.
109) Unger J. Don’t bet the ranch on ACOs. Journal of Family Practice. 61 (4). 185-186.
110) Unger J. Advances in Diabetes Therapies. Clinician Reviews. 2012. 22 (1). S19-S25.
111) Unger J. Intensification of type 2 diabetes in adolescents: Guess What? Exercise wins! Clinical Diabetes. 2012. 4 (30). 164-167.
112) Unger J. Pain no physician can take away. (Letter to the Editor). Journal of Family Practice. 2012. 61 (12). 718.
113) Unger J, Hinnen D, Schreiner B, Parkin C. Putting medications where they belong: Practical advice for managing type 2 diabetes in clinical practice. J Am Acad Nurse Pract. 2013. 25 (2). 65-76.
114) Unger J. Rationale use of GLP-1 receptor agonists in patients with type 1 diabetes. Curr Diab Rep. 2013. DOI 10.1007/s11892-013-0404-x. 1-8.
115) Unger J. Educating patients about hypoglycemia prevention and self-management. Clinical Diabetes. 2013. 31 (4). 179-188.
116) Unger J. What qualities define an expert family doctor? Clinical Diabetes. 2013. 31 (4). 145-147.
117) Unger J. What qualities define an expert family doctor? The patients have our backs. Correspondence and Clarifications. Clinical Diabetes. 2014. 32 (2). 57-58.
118)Unger J. Measuring the sweet smell of success in diabetes management. Annals of Translational Medicine. Doi: 10.3978/j.issn. 2305-5839.2014.08.04
119) Unger J. Med students: Look up from your EMRs. Journal of Family Practice. 2015. 64 (9). 517-518.
Publications: Medical Textbooks (Editorial Director)
1) Unger J- Guest Editor. Clinics in Family Medicine- Migraine. Sept. 2005. Elseiver Publications, Philadelphia, Pa.
2) Unger J, Schreiber CP (Eds). Disease-a-Month. Migraine. Vol. 52, No. 10.
October 2006. Mosby Publications. P 363-402.
3) Unger Jeff. – Guest Editor. Primary Care Clinics in Office Practice. Diabetes. 34 (4) (2007). Elsevier. Philadelphia, Pa.
Publications: Medical Textbook (Self-authored)
1) Unger Jeff. Diabetes Management in Primary Care. Lippincott, Williams and Wilkins. Philadelphia, PA. 2007.
2) Unger Jeff. Diabetes Management in Primary Care- Second Edition. Lippincott, Williams and Wilkins. Philadelphia, PA. 2012 ISBN 978-1-4511-4295-2
Publications: Textbook Chapters
1) Unger J. Migraine Headaches: An Historical Prospective, A Glimpse Into The Future and Migraine Epidemiology. In: Clinics in Family Practice. Sept. P 391-406. 2005 Elsevier Publications, Philadelphia, Pa.
2) Unger J. Migraine Headaches: A Historical Prospective, A Glimpse Into
The Future, and Migraine Epidemiology. In Disease-a-Month. Unger J,
Schreiber CP (Eds). 52 (10). Mosby. 367-382. Oct. 2006.
3) Introduction to Diabetes. In: Unger Jeff. Diabetes Management in Primary Care. Lippincott, Williams and Wilkins. Philadelphia, PA. 2007. P. 1-42.
4) Diagnosing and managing the metabolic syndrome in adults, children and adolescents. In: Unger Jeff. Diabetes Management in Primary Care. Lippincott, Williams and Wilkins. Philadelphia, PA. 2007. P. 43-87.
5) Polycystic ovary syndrome. In: Unger Jeff. Diabetes Management in Primary Care. Lippincott, Williams and Wilkins. Philadelphia, PA. 2007. P. 88-117.
6) Managing type 2 diabetes in adults. In: Unger Jeff. Diabetes Management in Primary Care. Lippincott, Williams and Wilkins. Philadelphia, PA. 2007. P. 118-191.
7) Physiologic insulin replacement therapy. In: Unger Jeff. Diabetes Management in Primary Care. Lippincott, Williams and Wilkins. Philadelphia, PA. 2007. P. 192-264.
8) Insulin pump therapy. In: Unger Jeff. Diabetes Management in Primary Care. Lippincott, Williams and Wilkins. Philadelphia, PA. 2007. P. 265-320.
9). Assessing glycemic control using home blood glucose monitoring, continuous glucose sensing, and glycated hemoglobin (A1C) testing. In: Unger Jeff. Diabetes Management in Primary Care. Lippincott, Williams and Wilkins. Philadelphia, PA. 2007. P. 321-362.
10) Management of diabetes in pregnancy, childhood, and adolescence. In: Unger Jeff. Diabetes Management in Primary Care. Lippincott, Williams and Wilkins. Philadelphia, PA. 2007. P. 363-404.
11) Lifestyle interventions for patients with diabetes. In: Unger Jeff. Diabetes Management in Primary Care. Lippincott, Williams and Wilkins. Philadelphia, PA. 2007. P. 405-464.
12) In-patient management of patients with diabetes. In: Unger Jeff. Diabetes Management in Primary Care. Lippincott, Williams and Wilkins. Philadelphia, PA. 2007. P. 465-503.
13) Screening, diagnosis, and management of diabetes-related complications. In: Unger Jeff. Diabetes Management in Primary Care. Lippincott, Williams and Wilkins. Philadelphia, PA. 2007. P. 504-617.
14) Amylin, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase IV (DPP-IV) inhibitors as novel treatments for diabetes. In: Unger Jeff. Diabetes Management in Primary Care. Lippincott, Williams and Wilkins. Philadelphia, PA. 2007. P. 618-646.
15) Managing mental illness in patients with diabetes. In: Unger Jeff. Diabetes Management in Primary Care. Lippincott, Williams and Wilkins. Philadelphia, PA. 2007. P. 647-682.
16) Unger, J. Management of Diabetes in Pregnancy, Childhood and Adolescence. In Primary Care Clinics In Office Practice. Jeff Unger, MD-Ed. 34 (4) (2007) 809-843.
17) Unger, J. Diagnosis and Management of Type 2 Diabetes and Prediabetes. In Primary Care Clinics In Office Practice. Jeff Unger, MD-Ed. 34 (4) (2007) 731–759.
18) Unger J, Cole BE. Recognition and Management of Diabetic Neuropathy. In Primary Care Clinics In Office Practice. Jeff Unger, MD-Ed. 34 (4) (2007) 887–913.
19) Unger J. Preface to Primary Care Clinics In Office Practice. Jeff Unger, MD-Ed. 34 (4). 2007. xi-xiv.
20) Unger J. Management of Type 1 Diabetes. In Primary Care Clinics In Office Practice. Jeff Unger, MD-Ed. 34 (4). 2007. 791-808.
21) Unger J. Fine-Tuning glycemic control using computerized downloading software: A case-based approach. In Insulin Therapy: Evolution and Practice. Endocrinology and Metabolism Clinics of North America. Irl Hirsch, Ed. Vol. 26; Supplement 2. 2007. P 46-68.
22) Unger J. Moriarty C. Preventing Type 2 Diabetes. Primary Care Clinics In Office Practice (Wellness and Prevention).Elsevier Publications. 35 (2008). 645-662.
23) Unger J. Pathogenesis of type 2 diabetes. A comprehensive analysis. In nutritional and therapeutic interventions for diabetes and metabolic syndrome. 29-42. Elsevier. 2012.
24) Introduction to diabetes. In Unger Jeff. Diabetes Management in Primary Care- Second Edition. Lippincott, Williams and Wilkins. 2012. Philadelphia, PA. 1-37.
25) Prediabetes. In Unger Jeff. Diabetes Management in Primary Care- Second Edition. Lippincott, Williams and Wilkins. 2012. Philadelphia, PA. 38-61.
26) Lifestyle interventions for patients with diabetes. In Unger Jeff. Diabetes Management in Primary Care- Second Edition. Lippincott, Williams and Wilkins. 2012. Philadelphia, PA. 62-112.
27) Polycystic ovary syndrome. In Unger Jeff. Diabetes Management in Primary Care- Second Edition. Lippincott, Williams and Wilkins. 2012. Philadelphia, PA. 113-138.
28) Prevention, diagnosis, and treatment of microvascular complications-Part 1, Diabetic Neuropathy. In Unger Jeff. Diabetes Management in Primary Care- Second Edition. Lippincott, Williams and Wilkins. 2012. Philadelphia, PA. 139-184.
29) Prevention, diagnosis, and treatment of microvascular complications-Part 2, diabetic nephropathy and diabetic retinopathy. In Unger Jeff. Diabetes Management in Primary Care- Second Edition. Lippincott, Williams and Wilkins. 185-216.
30) Exploring the association between diabetes and cardiovascular disease. In Unger Jeff. Diabetes Management in Primary Care- Second Edition. Lippincott, Williams and Wilkins. 2012. Philadelphia, PA. 217-259.
31) Comanaging disorders commonly associated with diabetes. In Unger Jeff. Diabetes Management in Primary Care- Second Edition. Lippincott, Williams and Wilkins. 2012. Philadelphia, PA. 260-295.
32) Comanaging mental illness in patients with diabetes. In Unger Jeff. Diabetes Management in Primary Care- Second Edition. Lippincott, Williams and Wilkins. 2012. Philadelphia, PA. 296-322
33) Diagnosis and management of T2DM. In Unger Jeff. Diabetes Management in Primary Care- Second Edition. Lippincott, Williams and Wilkins. 2012. Philadelphia, PA. 323-412.
34) Type 1 diabetes in adults. In Unger Jeff. Diabetes Management in Primary Care- Second Edition. Lippincott, Williams and Wilkins. 2012. Philadelphia, PA. 413-452.
35) Insulin initiation and intensification for patients with T2DM. In Unger Jeff. Diabetes Management in Primary Care- Second Edition. Lippincott, Williams and Wilkins. 2012. Philadelphia, PA. 453-490.
36) Insulin pumping and use of continuous glucose sensors in primary care. In Unger Jeff. Diabetes Management in Primary Care- Second Edition. Lippincott, Williams and Wilkins. 2012. Philadelphia, PA. 491-547.
37) Addressing cultural competency in diabetes care. In Unger Jeff. Diabetes Management in Primary Care- Second Edition. Lippincott, Williams and Wilkins. 2012. Philadelphia, PA. 548-582.
38) Unger J. Pathogenesis of Type 2 Diabetes-A comprehensive analysis. In Bagchi D. Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome. Elsevier Inc. Academic Press. 2012. 29-41
39) Unger J. White Russell. Diabetes Mellitus. In Textbook of Family Medicine 9th Ed. Rakel RE, Rakel DP Ed. Elsevier; Philadelphia, PA. 2016. P. 782-816.
Publications: Posters
1) Weidman, EW; Unger, JR; Blair, SD; Friesen, CP; Cady, RK; Hart, CC: “Access To Multiple Sumatriptan Formulations Enhances Patient Management of Migraine.” Poster presentation, American Association of Neurology. 2000.
2) Fred Freitag, Steven Greenberg, Jeffrey Unger, Gary Finlayson, Merle Diamond, Alan Fisher, Joseph Hulihan Effect of Time to Treatment on Headache Duration: Interim Results From AIMS: AXERTâ 12.5 mg Time vs Intensity Migraine Study . American Headache Society Poster S69. Philadelphia, Pa. 6/25/05
3) Smith R, Smith T, Banks JW, Ruoff G, Unger JR, Hee A. Patients benefit when using zolmitriptan as part of a guideline-based approach to migraine management in primary care. 16th Migraine Trust Symposium. London, U.K. Sept. 18-20. 2006.
4) Smith T, Banks JW, Unger J, Ruoff GE, Hee A, Smith R. Effective management of acute migraine in primary care using a Headache Care for Practicing Clinicians (HCPC) guidelines-based treatment strategy. American Academy of Neurology. Poster Session P06. Boston, MA. May 3, 2007.
5) Rodbard H, Schnell O, Unger J. Rees C, Parkin C, Jelsovsky Z, Amstutz L, Wegmann N, Schweiter M, Wagner R. Decision Support Tools Dramatically Improve Clinicians’ Ability To Interpret Structured SMBG Data. Late-Breaking Poster presentation. ADA 71st Scientific Session. San Diego,Ca. June 24-28, 2011. 24-LB.
6) Blonde L, Endahi L, Lassota N, Unger J. Insulin degludec is highly efficacious regardless of diabetes duration or body mass indes: A cross-trial evaluation. Poster Presentation AACE 21st Annual Scientific and Clinical Congress. 23-27 May, 2012. Philadelphia, PA. USA.
7) Bergenstal R, Bhargave A, Jain R, Unger J, Christensen TE, Mersebach H, Gough S. Improved patient-reported outcomes with insulin degludec 200 U/mL (IDeg U200) versus insulin glargine in insulin-naïve people with type 2 diabetes. AACE 21st Annual Scientific and Clinical Congress. 23-27 May 2012. Philadelphia, PA. USA.
8) Bergenstal R, Bhargava A, Jain RK, Unger J, Christensen TE, Rana A, Gough. Improved patient-reported outcomes with insulin degludec 200 U/mL (Deg U200) versus insulin glargine in insulin-naïve people with type 2 diabetes. Abstract 3672 QoL. AACE 21st Annual Scientific and Clinical Congress. 23-27 May 2012. Philadelphia, PA. USA
Publications: Consumer
1). When Diabetes Hurts: The Pain of Diabetic Neuropathy. The Female Patient Supplement. 10-12. October 2005.
2) Insulin Therapy: Transforming the Most Important Discovery of Modern Medicine Into A Powerfully Effective Drug.
3) Migraine Headaches: Treating With Triptans. Migraine Consult Collection. A Supplement to the Female Patient. Spanish and English Version Published. March 2007.
4) The Migraine Diary: Your Partner In Headache Treatment. Migraine Consult Collection. A Supplement to the Female Patient. Spanish and English Version Published. March 2007.
5) Migraine Prevention: Prophylaxis Medications. Migraine Consult Collection. A Supplement to the Female Patient. Spanish and English Version Published. March 2007.
6) Unger J. Headache and Your Primary Care Physician: How to Approach the Issues. ACHE Newsletter. Vol. 12, Issue 2. Summer 2001.
7) Unger J. Trigeminal Neuralgia. ACHE Headache Newsletter. Vol. 12, Issue 4. P. 8. 2002.
8) Liberate Health Condition Library. Type 1 Diabetes App: 4/14. https://itunes.apple.com/us/app/liberate/id734648415?mt=8.
Publications: Spiritual
• Unger, Jeff. Hope and Prayer In The ICU. Farbrengen (Chabad). Fall Issue. 5768. 27-28
• Unger, Jeff. A Slice of Life. Hope and Prayer in The ICU. 11/2-21/07. Cheshlan, 5768. L’Chaim. 993. Chayei Sara.
• Unger, Jeff. So I may be at risk for diabetes? Oy vey! Now What? Jewish Impact Magazine. Winter 2007/5768. 64-65.
• Jeff Unger, MD. The True Meaning of “A Really Bad Day” The Daily Bulletin. 8/21/12. http://www.dailybulletin.com/opinions/ci_21356586/true-meaning-really-bad-day
Publications: Primary Care Metabolic Group Blogs (http://pcmg2.blogspot.com/search?updated-min=2008-01-01T00%3A00%3A00-08%3A00&updated-max=2009-01-01T00%3A00%3A00-08%3A00&max-results=9)
1. Evaluation and treatment of primary androgen deficiency syndrome in male patients. Feb. 2008
2. “Doctor, how should I manage a patient with ‘prediabetes’?” March 2008
3. Does your patient qualify as a “brittle diabetic?” April 2008
4. Some random thoughts about ACCORD. May 2008
5. A case of lipoatrophy causing loss of glycemic control. June 2008
6. Advocating individualization of glycemic control in high risk patients with type 2 diabetes (T2DM). July 2008
7. Vitamin D Deficiency and All Cause Mortality. August. 2008
8. Neuroinflammation as a Cause of Chronic Pain. Oct. 2008
9. Vitamin D- Part 2. Nov. 2008
10. JUPITER Lights Up the Statin Universe. Dec. 2008
11. Thinking Beyond Glycemic Control For Patients With Type 2 Diabetes. March 2009
12. Evaluation and management of patients with low HDL cholesterol. June 2009
13. Ask not what you can do for your A1C, ask what your A1C can do for you. Oct. 2009
Publications: Vanguard Diabetes Blogs
1. Monogenetic diabetes: A Case of Misidentity Posted 6/12/12. diabetesvanguard.com/category/blogs/diagnosis/
Publications: Diabetic Lifestyle Web Site
1. The Frustrated Patient (6/30/13)
http://www.diabeticlifestyle.com/professional/case-studies/frustrated-patient-diabetes
Publications: Medscape (CME) and others
1. Differential Effects of GLP-1s and DPP-4s on Weight Loss and Beta-Cell Function: http://cmsprepub.medscape.com/viewarticle/587891
2. Impact of Nausea and vomiting on weight loss in patients using GLP-1 agonists: http://cme.medscape.com/viewarticle/701915
3. GLP-1 agonists. Impact on beta cell function: http://cme.medscape.com/viewarticle/702174
4. Impact of Combined GLP-1 Receptor Agonist and Thiazolidinedione Therapy on Weight: http://cme.medscape.com/viewarticle/702488
5. Advances in Glucagon-like Peptides for the Treatment of Type 2 Diabetes — Volume 5: http://cme.medscape.com/viewprogram/30401
6. Advances in Glucagon-like Peptides for the Treatment of Type 2 Diabetes-Volume 6: http://cme.medscape.com/viewarticle/712358
7. Meeting the Needs of Patients With T2DM: Emerging Clinical Data With GLP-1 Analogues: http://cme.medscape.com/viewarticle/725993
8. Veronica visit 1: 57-year old African American female with 9-year history of type 2 diabetes and newly diagnosed albuminuria. RMEI. http://rmei.realcme.com/cms/node/286121. (10/22/12).
9. Veronica visit 2– Motivational interviewing with a patient with type 2 diabetes and newly diagnosed albuminuria. RMEI. http://rmei.realcme.com/cms/node/286982 (10/22/12).
10. Individualizing T2DM treatment: Determining optimal pathways that lead to achieving target goals. Supplement to Endocrine Today. Henry RR, Vonseca VA, Unger J, Edelman SV. Sept. 2013. 1-23
11. The Role of the Kidney in Glucose Homeostasis. Primary Care Network. 3/18/14. https://4d.primarycarenet.org/4DACTION/w_PI173/
Publications: Internal Medicine Alert (CME)
1. Optimal management for obese patients with type 2 diabetes: surgery vs medical therapy. Internal Medicine Alert. 2012. 34 (18). 137-139.
2. Spiritual assessment in primary care. Internal Medicine Alert. 2012. 34 (19) 148-149.
3. Updating the 2000 published guidelines for preventing episodic migraine: Is anyone listening? Internal Medicine Alert. 2012. 34 (20). 155-156.
4. At last…Type 1 diabetes can be prevented (But only in Rats). Internal Medicine Alert. 2013. 35 (1). 4-5.
5. Are you feeling the heat of professional burnout? You are probably in good company! Internal Medicine Alert. 2013. 35 (2). 11-12.
6. Does intensive lifestyle intervention reverse type 2 diabetes? Internal Medicine Alert. 2013. 35 (5). 35-36.
7. An evidence-based insulin intensification regimen. Internal medicine alert. 2014. 36(4). 25-26
8. Changes in diabetes-related complications in the United States. IMA. 36 (10) 76-77
9. Early Intensive Therapy in Patients with type 2 diabetes reduces glycemic variability: What are the clinical implications. IMA. 2014. 36 (11) 81-82
10. Liraglutide Preserves Beta Cell Function — Well, Kind of… IMA. 2015. Jan. 15
11. Should Metformin Use In Patients With Chronic Kidney Disease Be Expanded? IMA. 2015. Jan. 29.
12. Hypoglycemia Increases Cardiovascular Risk in Patients With Type 1 and Type 2 Diabetes. IMA. 2015. Feb. 14.
13. Should Clinicians Discuss Resumption of Sexual Activity Following an Acute MI?IMA. 2015. Feb. 12.
14. The Economic Burden of Undiagnosed Pre-diabetes. IMA. 2015. Feb 12.
Manuscript Reviewer for the Following Indexed/Peer-Reviewed Publications:
1. Diabetes Care
2. Journal of Headache
3. Emergency Medicine
4. Diabetes Research and Clinical Practice
5. American Journal of Medicine
6. The Tohuko Journal of Experimental Medicine
7. Diabetes, Obesity and Metabolism
8. Expert Review of Medical Devices
9. Diabetes Medicine
10. Journal of Diabetes and Its Complications
11. Journal of Family Practice (Editorial Board- Jan. 2011)
12. Clinical Diabetes (Editorial Board- Feb. 2012)
13. Internal Medicine Review (Associate Editor- Aug. 2012)
Peer Reviewed Journal Editorial Board Appointments
1. Journal of Family Practice (2011-2013)
2. Internal Medicine Review (2012-2013)
3. Clinical Diabetes (2012-2013)
4. Diabetes Care (2012-2015)
5. Journal, Diabetes and the Pancreas (2014)
6. Emergency Medicine (2008-2014)
Hospital Affiliations:
• Doctor’s Hospital: Montclair, Ca. 2002. Attending Physician. Courtesy Staff.
PROFESSIONAL ASSOCIATION COMMITTEE APPOINTMENT:
American Association of Clinical Endocrinologist Primary Care Physician Education Initiative Committee Member- 2012-15
AWARDS RECEIVED:
• Recipient of the National Headache Foundation (NHF) Lectureship Award-2000.
• American Diabetes Association, Orange County Chapter, Father of the Year Award Recipient June 2009
Fellow of the American Association of Clinical Endocrinologists (FACE)
• Notified February 2014. Induction 5/17/2014
SPECIAL INTERESTS:
• Consulting Physician for the WORLD WRESTLING FEDERATION 1989-2004.
• Consulting Physician for WORLD CHAMPIONSHIP WRESTLING since 1994-2001.
• Primary Care Physician for Rancho Cucamonga Quakes professional baseball (affiliate of Los Angeles Angels of Anaheim) team 4/01 to 9/2010.
MEDICAL SPECIAL INTERESTS:
1. Diabetes management
2. Intensification of type 1 and type 2 diabetes
3. Latent autoimmune diabetes
4. Insulin pump therapy
5. Continuous glucose sensors
6. Glucose meter software
7. Managing comorbid mental illness
8. GLP-1 receptor agonists
9. Managing microvasular complications (chronic kidney disease and neuropathy)
10. Lifestyle intervention
11. Hypoglycemia
12. Disturbed eating in type 1 and type 2 diabetes
13. Advanced self-glucose monitoring
14. All aspects of headache management
15. Chronic pain evaluation and treatment
16. Bipolar depression
17. Sports medicine
18. Medical publishing
19. Heroin dependency, opioid dependency, alcohol dependency. Suboxone and vivitrol prescriber
Clinical investigational drug studies performed at Catalina Research Institute, LLC from 2008 to the present as primary or subinvestigator:
1. Abbott Laboratories
A Randomized, Double-Blind, Placebo-Controlled Study Using a Bayesian Adaptive Design to Evaluate the Efficacy and Safety of XXX in Subjects With Mild-to-Moderate Alzheimer’s Disease on Stable Doses of Acetylcholinesterase Inhibitors.
2. Allergan Pharmaceuticals
A Multi-center, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose, Parallel Design, Dose Ranging Study of the Safety and Efficacy of XXX in Patients with Painful Diabetic Peripheral Neuropathy.
3. Akros
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi- Center, Parallel Group Study Evaluating the Efficacy, Safety and Pharmacokinetics of XXX Administered for 12 Weeks in Untreated or Metformin-treated Type 2 Diabetic Patients (BALANCE)
4. A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study to Evaluate the Effect of Two Doses of XXX on Fasting Serum Triglyceride Levels in Patients with Persistent High Triglyceride Levels (≥200 mg/dL and <500 mg/dL) Despite Statin Therapy
5. Amylin
An Open-Label Study to Characterize Product Complaints and Patient Satisfaction with use of the Symlin-pen™ Pen-Injector.
6. Arena
A 52-Week, Double-blind, Randomized, Placebo-controlled, Parallel-Group Study to Assess the Safety and Efficacy of XXX in Overweight and Obese Patients XXX.
7. Arena
Title: A 52-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of XXX in Overweight and Obese Patients with Type 2 Diabetes Mellitus Managed with Oral Hypoglycemic Agent(s).
8. Astra-Zeneca
A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Efficacy and Safety Study of XXX in the Treatment of Generalized Anxiety Disorder (GAD).
9. Astra-Zeneca
A 24-week, multicentre, randomised, double-blind, age-stratified, placebo controlled phase III study with a 28-week extension period to evaluate the efficacy and safety of XXX 10 mg once daily in patients with type 2 diabetes and cardiovascular disease, who exhibit inadequate glycaemic control on usual care.
10. Astra-Zeneca
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XXX in Patients with Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC).
11. Bristol-Myers Squibb
A Multicenter, Randomized, Double-Blind, Placebo-controlled Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of XXX in Subjects with Type 2 Diabetes with Inadequately Controlled Hypertension treated with an angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) and an Additional Antihypertensive Medication.
12. Bristol-Myers Squibb
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of XXX in Subjects with Type 2 Diabetes with inadequately controlled hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
13. Cephalon
A Randomized, Double Blind, Active Controlled Crossover Study to Evaluate the Efficacy and Safety of XXX Buccal Tablets Compared With Immediate Release Oxycodone for the Management of Breakthrough Pain in Opioid Tolerant Patients With Chronic Pain, Followed by a 12 Week Open Label Extension to Evaluate the Impact of XXX Buccal Tablets on Patient Outcomes.
14. Daiichi Sankyo Pharma Development
A Randomized, Double-Blind, Parallel Group Study Evaluating The Efficacy And Safety Of Co-Administration Of A Triple Combination Therapy of XXX, XXX and XXX, In Subjects With Hypertension.
15. Daiichi-Sankyo
A Randomized, Double-Blind, Placebo-controlled, Parallel-Group Study of the Efficacy and Safety of XXX as add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus.
16. Eli Lilly & Company
The Impact of XXX versus Insulin Glargine for Patients with Type 2 Diabetes Mellitus Advanced to Multiple Injection Bolus Insulin with Insulin Lispro: a Double-Blind, Randomized, 26-Week Study The IMAGINE 4 Study.
17. Eli Lilly & Company
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly XXX with Once-Daily Liraglutide in Patients with Type 2 Diabetes (AWARD-6: Assessment of Weekly Administration of LY2189265 in Diabetes – 6).
18. Eli Lilly & Company
The Impact of XXX versus Insulin Glargine for Patients with Type 2 Diabetes Mellitus Advanced to Multiple Injection Bolus Insulin with Insulin Lispro: a Double-Blind, Randomized, 26-Week Study The IMAGINE 4 Study.
19. Forest Research Institute
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of XXX Added to Antihypertensive Treatment with Lisinopril or Losartan in Patient with Hypertension.
20. Forest Research Institute
Glycemic Effects of XXX Compared with Metoprolol Extended Release and Compared with Hydrochlorothiazide in Hypertensive Patients with Type 2 Diabetes Mellitus” A Pilot Study.
21. Forest Research Institute
Metabolic Effects of XXX Compared to Metoprolol ER in Hypertensive Patients with Impaired Glucose Tolerance or Impaired Fasting Glucose.
22. Forest Research Institute
A Multicenter, Prospective, Randomized, Double-blind, Placebo-Controlled, Dose Titration Study of XXX Monotherapy in Hispanic Patients with Stage 1 or Stage 2 Hypertension.
23. GlaxoSmithKline
A Randomized, Double-Blind, Placebo and Active Controlled, Parallel Group, Multi-Center Study to Determine the Efficacy and Safety of XXX When Used in Combination with Metformin Plus Sitagliptin, Metformin Plus Glimepiride and Metformin Plus Placebo in Subjects With Type Type 2 Diabetes Mellitus.
24. GlaxoSmithKline
A Randomized, Open-Label, Parallel Group, Multi-Center Study to Determine The Efficacy and Long Term Safety of XXX Compared With Insulin in subjects With Type 2 Diabetes Mellitus.
25. GlaxoSmithKline
A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Group, Multicenter Study to Determine the Efficacy and Safety of XXX Administered in Combination With Metformin and Glimepiride Compared with Metfomin Plus Glimepride and Placebo and With Metformin Plus Glimepiride and Pioglitazone in Subjects With Type 2 Diabetes Mellitus.
26. GlaxoSmithKline
A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of XXX Administered in Combination with Insulin Glargine as Compared with the Combination of Insulin Galrgine and Preperandial Lispro Insulin in Subjects with Type-2 Diabetes Mellitus.
27. Grunenthal
A Randomized, Multicenter, Double-Blind, Parallel-Group Trial to Assess The Analgesic Efficacy and Safety of a New Analgesic Compared With Placebo in Subjects With Painful Diabetic Peripheral Neuropathy.
28. Hoffman-LaRoche
A multicenter, randomized, double blind (double dummy), active comparator controlled study to compare the efficacy, safety and tolerability of XXX versus XXX in type 2 diabetes patients inadequately controlled with sulfonylurea (SU) monotherapy or metformin plus sulfonylurea combination therapy.
29. Intarcia Diabetes 02. A Phase 2, Randomized, Two-Stage, Open-Label, Multi-Center, 24-Week Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Subjects with Type 2 Mellitus.
30. MAP Pharmaceuticals, Inc
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of XXX In Adult Migraines for a Single Migraine Followed by Open –Label Extensions to 26/52 Weeks.
31. Merck
A Multicenter, Randomized, Double-Blind Study of the Co-Administration of XXX and XXX in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control.
32. Merck
A Study of XXX for Prevention of Menstrually Related Migraine in Female Patients.
33. Merck
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of XXX in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Alone or in Combination With Metformin.
34. Metabolic Solutions. A Phase 2B, Randomized, Double-Blind, Comparator-and Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of XXX in Type 2 Diabetic Patients.
35. Novo-Nordisk
The effect of insulin XXX in combination with liraglutide and metformin compared to XXX and metformin in subjects with type 2 diabetes. A 26-week, randomised, open-label, parallel-group, multicentre, multinational trial with a 26-week.
36. Novo-Nordisk
Maintain Effect of XXX In Obesity Treatment: Effect of XXX on long-term weight maintenance following weight loss induced by a 12 week low calorie diet in obese subjects; A 52 week randomized, double-blind, placebo controlled, parallel group, multi-centre trial with a 12 week follow-up period.
37. Novo-Nordisk
A 26-Week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-To-Target Trial Comparing the Efficacy and Safety of XXX 200 U/Ml And Insulin Glargine, Both Injected Once Daily in Combination with Oral Anti-Diabetic Drugs (OADS), in Insulin Naïve Subjects with Type 2 Diabetes Mellitus Currently Treated with OAD(S) Qualifying for Intensified Treatment.
38. Novo-Nordisk
A 16-week, uncontrolled, single armed, multicentre, treat-to target trial assessing the implications of switching from insulin glargine once daily (OD) to XXX 200 U/ml three times weekly in subjects with type 2 diabetes mellitus currently treated with insulin glargine OD and oral antidiabetic drugs (OADs).
39. Novo-Nordisk
A Long-term, Multi-centre, International, Randomised Double-Blind, Placebo-controlled Trial to Determine XXX Effects on Cardiovascular Events.
40. Novo-Nordisk
A 26-Week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With XXX in combination with metformin.
41. Novo-Nordisk
A Trial Comparing the Efficacy and Safety of Insulin XXX 200 U/Ml and Insulin XXX 100 U/Ml in Subjects With Type 2 Diabetes Mellitus.
42. Novo-Nordisk
DUAL Action of XXX and insulin degludec in type 2 diabetes. A trial comparing the efficacy and safety of XXX and XXX in subjects with type 2 diabetes. A 26 week randomized, parallel three-arm, open-label, multi-centre, multinational treat-to-target trial comparing fixed ratio combination of insulin XXX and XXX versus XXX or XXX alone, in subjects with type 2 diabetes treated with 1-2 oral anti-diabetic drugs (OADs) with a 26 week extension.
43. Novo-Nordisk, A Trial Comparing The Efficacy and Safety of XXX/XXX Once Daily in Insulin-Naïve Subjects with Type 2 Diabetes Mellitus When Using Two Different Titration Algorithms.
44. Ortho-McNeil Johnson
A Single-Arm Evaluation of the Safety and of XXX Extended-Release (ER) in Subjects with Schizophrenia or Schizoaffective Disorder with hepatic Disease.
45. Proctor & Gamble
A Phase II, Randomized, Adaptive Design, Multicenter, Parallel Group, Placebo-controlled, 58 Day, Dose-ranging Study of XXX in Patients with Postprandial Distress Syndrome.
46. Proctor & Gamble
A Phase II, Randomized, Placebo-controlled Study of XXX in Patients with Chronic Idiopathic Constipation.
47. Proctor & Gamble
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 52week study to Evaluate the Endometrial Safety of XXX (300 mcg/day) in Naturally Postmenopausal Women with Hypoactive Sexual Desire Disorder.
48. Purdue Pharma. A Multi-center, Randomized, Double-blind, Placebo-controlled Study with an Open-label Run-in to Assess the Efficacy, Tolerability, and Safety of XXX 10 or XXX 20 Compared to Placebo in Opioid-naïve Subjects with Moderate to Severe, Chronic Pain due to Osteoarthritis of the Knee.
49. Sangamo BioSciences, Inc.
A Phase 2B Repeat Dosing Clinical Trial of XXX in Subjects with Moderately Severe Diabetic Neuropathy.
50. Sanofi-Aventis
A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week main treatment period and an extension assessing the efficacy and safety of XXX in patients with Type 2 diabetes insufficiently controlled with basal insulin.
51. Sanofi-Aventis 6016.PI. A Randomized, Double-Blind, Placebo-Controlled, 2-Arm Parallel-Group, Multicenter Study with a 24-Week Main Treatment Period and an Extension Assessing the Efficacy and Safety of AVE0010 on Top of Pioglitazone in Patients with Type 2 Diabetes Not Adequately Controlled with Pioglitazone
52. Sanofi-Aventis 1569. PI A Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 Versus Ezetimibe in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Statin Therapy
53. Sanofi-Aventis. Sub investigator A 24 Week, Multicenter, Double-Blind, Randomized, Parallel-Group, Dose Ranging Study of the Efficacy and Safety of Oral Doses of XXX 1625 5, 10 and 30 mg and placebo on top of an established treatment regimen of either Olanzapine, Risperidone/paliperidone, quetapine or aripirazole Monotherapy in the treatment of Cognitive Impairment in Schizophrenia.
54. Sanofi-Aventis A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using tolterodine as a study calibrator, to evaluate efficacy and safety of XXX in women with overactive bladder including urge urinary incontinence.
55. Sucampo Pharmaceuticals A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of XXX in Patients with Opioid-induced Bowel Dysfunction.
56. A Phase II, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate Daily Treatment with XXX in Subjects with Type 2 Diabetes.
57. TWI Biotechnology, A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Phase II Study of XXX in Patients with Type 2 Diabetes Mellitus.
58. Warner Chilcott A Randomized, Placebo-controlled, Double-Blind, Parallel Design, Phase 3 Study to Assess the Safety and Efficacy of XXX Tablets in Male Subjects with Erectile Dysfunction.
59. Warner Chilcott, An Open-Label Phase 3 Study to Evaluate the Long-Term Safety and Efficacy of XXX Tablets in Male Subjects with Erectile Dysfunction.
60. Wyeth A Multi-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate Functional Outcome in Outpatients with Major Depressive Disorder treated with XXX Sustained Release.
61. XOMA, Inc. A Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of the Safety and Efficacy of XXX in Subjects with Type 2 Diabetes Mellitus on Stable Metformin Monotherapy.
62. XOMA HTN 5400. PI. Perindopril Amlodipine for the Treatment of Hyupertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluation the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate versus Perindopril Erbumine and Amplodipine Besylate in Subjects with Essential Hypertension.
63. Novo Nordisk. NN1250-3672 Novo-Nordisk, A 26-Week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-To-Target Trial Comparing the Efficacy and Safety of Soluble Insulin Basal Analogue (SIBA) 200 U/Ml And Insulin Glargine, Both Injected Once Daily in Combination with Oral Anti-Diabetic Drugs (OADS), in Insulin Naïve Subjects with Type 2 Diabetes Mellitus Currently Treated with OAD(S) Qualifying for Intensified Treatment2010
64. Novo Nordisk. NN1250-3839 Novo-Nordisk, A 16-week, uncontrolled, single armed, multicentre, treat-to target trial assessing the implications of switching from insulin glargine once daily (OD) to (study drug) 200 U/ml three times weekly in subjects with type 2 diabetes mellitus currently treated with insulin glargine OD and oral antidiabetic drugs (OADs) 2010.
65. Novo Nordisk BEGIN. NN 1250-3923. PI. A trial comparing the efficacy and safety of insulin degludec 200 U/mL and insulin degludec 100 U/mL in subjects with type 2 diabetes mellitus.
66. Novo Nordisk DM2 BOOST. 3844. PI. A trial comparing the efficacy and safety of insulin degludec/insulin aspart once daily in insulin-naive subjects with type 2 diabetes mellitus when using two different titration algorithms
67. Novo Nordisk. EX2211-3748 “LEADER” Novo-Nordisk, A Long-term, Multi-centre, International, Randomised Double-Blind, Placebo-controlled Trial to Determine (study drug) Effects on Cardiovascular Events 2010 (Member of National Expert Panel)
68. Novo Nordisk. NN304-3785 “Levemir Diet” A 26-Week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on metformin.
69. Repros Low Testosterone ZA-300. PI. An Open Label, Escalating Dose, 6 Month Phase III Safety Study of Enclomiphene Citrate in the Treatment of Men with Secondary Hypogonadism.
70. Roche Diabetes 025. PI. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess the Efficacy, Safety and Tolerability of Aleglitazar added to a Sulfonylurea or Added to a Sulfonylurea in Combination with Metformin in Patients with Type 2 Diabetes Mellitus (T2d) Inadequately Controlled with Sulfonylurea Monotherapy or with Sulfonylurea Plus Metformin Combination Therapy.
71. Roche EMERGE. PI. A multicenter, randomized, double blind (double dummy), active-comparator controlled study to compare the efficacy, safety and tolerabilty of taspoglutide versus pioglitazone in type 2 diabets patients inadequately controlled with sulfonylurea (SU) monotherapy or metformin plus sylfonylurea combination therapy.
72. Amarin cholesterol/Cardiovascular 0019. (Sub-investigator). A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA Intervention Trial).
73. Boehringer Ingelheim DM 2 1245.31 Extension trial. Primary investigator. A phase III double-blind, extension, placebo-controlled parallel group safety and efficacy trial of BI 10773 (10 and 25mg once daily) and sitagliptin (100mg once daily) given for minimum 76 weeks (incl. 24 weeks of preceding trial) as monotherapy or with different back-ground therapies in patients with type 2 diabetes mellitus previously completing trial 1245.19, 1245.20 or 1245.23.
74. Dexcom Glucose Monitoring 0920. Primary investigator. Evaluation of Glycemic Control Using Adjunctive Continuous Glucose Monitoring with the Dexcom G4System GLYCOAIM Study.
75. Lilly DM2 BIAM. Primary investigator. The Impact of LY2605541 versus Insulin Glargine for Patients with Type 2 Diabetes Mellitus Advanced to Multiple Injection Bolus Insulin with Insulin Lispro: a Double-Blind, Randomized, 26-Week Study The IMAGINE 4 Study.
76. Lilly GBDE. Primary investigator. A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide with Once-Daily Liraglutide in Patients with Type 2 Diabetes (AWARD-6: Assessment of Weekly AdminstRation of LY2189265 in Diabetes )
77. Merck DM2 260. Sub investigator.A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Safety and Insulin-Sparing Efficacy of the Addition of Sitagliptin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Alone or in Combination With Metformin.
78. Roche Diabetes 205. Primary investigator. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess the Efficacy, Safety and Tolerability of Aleglitazar added to a Sulfonylurea or Added to a Sulfonylurea in Combination with Metformin in Patients with Type 2 Diabetes Mellitus (T2d) Inadequately Controlled with Sulfonylurea Monotherapy or with Sulfonylurea Plus Metformin Combination Therapy.
79. Roche Diabetes 035. Primary investigator. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Iii Study To Assess The Efficacy, Safety And Tolerability Of Aleglitazar Plus Metformin Combination Therapy Compared With Placebo Plus Metformin In Patients With Type 2 Diabetes Mellitus (T2d) Inadequately Controlled With Metformin Monotherapy.
80. Roche Diabetes BC28034. Primary investigator. A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Assess The Efficacy, Safety and Tolerability of Aleglitazar Monotherapy Compared with Placebo in Patients with Type 2 Diabetes Mellitus (T2d) Who Are Drug-Naiive To Anti-Hyperglycemic Therapy.
81. Sanofi Hypercholestrolemia 1569. Sub investigator. A Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 Versus Ezetimibe in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Statin Therapy.
82. AstraZeneca Diabetes 0019. PI. A 24-week, multicentre, randomised, double-blind, age-stratified, placebocontrolled phase III study with a 28-week extension period to evaluate the efficay and safety of dapagliflozin 10 mg once daily in patients with type 2 diabetes and cardiovascular disease, who exhibit inadequate glycaemic control on usual care.
83. Akros Diabetes 002. Sub-I. A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients with Type 2 Diabetes Mellitus.
84. Boehringer Ingelheim DM 2, 1245.20. PI. A phase III randomised, double-blind, placebo-controlled parallel group efficacy and safety study of (study drug) and sitagliptin administered orally over 24 weeks, in drug naïve patients with type 2 diabetes mellitus and insufficient glycaemic control despite diet and exercise.
85. Boehringer Ingelheim DM 2 1245.31 Extension. A phase III double-blind, extension, placebo-controlled parallel group safety and efficacy trial of BI 10773 (10 and 25mg once daily) and sitagliptin (100mg once daily) given for minimum 76 weeks (incl. 24 weeks of preceding trial) as monotherapy or with different back-ground therapies in patients with type 2 diabetes mellitus previously completing trial 1245.19, 1245.20 or 1245.23.
86. Boehringer Ingelheim DM2 1264.3. PI. A randomised, double-blind parallel group study to compare the efficacy and safety of initial combination therapy with linagliptin 5 mg + pioglitazone 15 mg, 30 mg, or 45 mg, vs. monotherapy with pioglitazone (15 mg, 30 mg, or 45 mg) or linagliptin 5 mg once daily for 30 weeks, followed by a 54 week blinded trial period on linagliptin 5 mg + pioglitazone 30 or 45 mg versus pioglitazone monotherapy 30 or 45 mg or linagliptin 5 mg in type 2 diabetic patients with insufficient glycaemic control on metformin.
87. ConjuChem DM2 103. PI. A Randomized,Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of 17 Weeks of Weekly Injections of CJC-1134-PC in Patients with Type 2 Diabetes Mellitus on Metformin Monotherapy.
88. Daiichi Sankyo Neuropathy 201. PI. A Randomized, Double-Blind, Placebo and Active Comparator-Controlled Study of DS-5565 for Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy.
89. Johnson and Johnson Diabetes 3002. PI. A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin and Suphonylurea Therapy.
90. GSK 86 Harmony. PI. A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination with Insulin Glargine as Compared with the Combination of Insulin Galrgine and Preperandial Lispro Insulin in Subjects with Type-2 Diabetes Mellitus
ADVISORY BOARD APPOINTMENTS:
• Novo Nordisk Primary Care 2004
• Novo Nordisk Degludec National Advisory Board 2006
• Lilly Primary Care 2003
• Sanofi-Aventis Primary Care 2003 and 2011
• Pfizer 2005
• ProEthic Pharmaceuticals-2006
• Amylin Pharmaceuticals- 2001
• Nektar pharmaceuticals-2008
• Roche Pharmaceuticals-2009
• KOWA Pharmaceuticals-2009
• NicOx Pharmaceuticals-2009
• URL Pharma PCP Advisory Board-2010
• Takeda Pharmaceuticals-2010
• Novo Liraglutide National Scientific Advisory Board
• Allergan National Advisory Board (Obesity) 2011
• LEADER (EX2211-3748) National Expert Panel -2010
• Bydureon Primary Care Advisory Board 2010
• Lanagliptin Boehringer-Ingelheim Advisory Board 2010
• Abbott Pharmaceuticals PCP National Advisory Board 2011
• Novo Nordisc Degludec and Degludec Plus International Advisory Board 2011
• Allergan PCP Advisory Board (BOTOX) 2011
• Halozyme PCP Advisory Board 2012
• Janseen Pharmaceuticals 2012
• Genentech Pharmaceuticals 2012
• IDegLira International Ad Board (Novo Nordisk) 2014
• SUSTAIN Trial National Investigator (Novo Nordisk) 2014
• Double Helix 2014
• Proteus pharmaceuticals 2014
• Dream Pharmaceuticals 2014
• Ictarcia Advisory Board 2015
EDITORIAL BOARD APPOINTMENT
·Diabetes Care (Editorial reviewer since 2002)
• The Female Patient (Associate Editor since 2002)
• Emergency Medicine (Associate Editor and Reviewer since 2002)
• Clinical Diabetes Editorial Board 1991-2001. 2012-2013.
• Medical Crossfire 2001
• Quadrant Medical Education (Editor-in-Chief 2006-2008)
• Primary Care Metabolic Group Editor and Contributor 2007
• Journal of Family Practice-2009 -2013 Editorial Board
• Diabetes, Obesity and Metabolism (Reviewer- 2010)
• Diabetes Therapy (Reviewer-2010)
• Journal of Diabetology (Reviewer- 2010)
• Clinical Diabetes – Editorial Board (2012)
• Diabetes Care-Associate Editor (2013)
• Internal Medicine Review-Associate Editor (2013)
• URB Publishing (Endocrinology Network)-Editorial Board (2014)